News

The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the

Under the terms of the worldwide exclusive licensing agreement, Pfizer will pay an upfront license fee of $250m to Akcea and Ionis. The fee will be split equally

Beovu, which is also known as RTH258, is now the first anti-VEGF to be approved by the regulator. According to Novartis, the drug can offer greater fluid resolution

The regulator approved the new drug application (NDA) for PF708, which was submitted under the 505(b)(2) regulatory pathway with Eli Lilly and Company’s Forteo as the reference medicine.

The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial, which achieved their primary objective of usability and pharmacokinetic (PK)

Johnson & Johnson (J&J) will use the investment to advance research and development and delivery programmes to eliminate both diseases by 2030. The company will appoint a team

Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts. A non-invasive, once-daily, epicutaneous

The company was founded on computationally designed self-assembling virus-like particle (VLP) technology developed at the Institute for Protein Design (IPD) at University of Washington School of Medicine (Cell

Goldfinch Bio will assume all development and commercialization responsibilities for the treatment of rare and metabolic kidney diseases worldwide. However, the agreement grants Takeda the option, prior to